961 related articles for article (PubMed ID: 15466650)
1. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
[TBL] [Abstract][Full Text] [Related]
2. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
3. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Evgenov OV; Kohane DS; Bloch KD; Stasch JP; Volpato GP; Bellas E; Evgenov NV; Buys ES; Gnoth MJ; Graveline AR; Liu R; Hess DR; Langer R; Zapol WM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1138-45. PubMed ID: 17872487
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
[TBL] [Abstract][Full Text] [Related]
5. Effect of inhaled nitric oxide on experimentally induced pulmonary hypertension in neonatal foals.
Lester GD; DeMarco VG; Norman WM
Am J Vet Res; 1999 Oct; 60(10):1207-12. PubMed ID: 10791931
[TBL] [Abstract][Full Text] [Related]
6. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
Pankey EA; Bhartiya M; Badejo AM; Haider U; Stasch JP; Murthy SN; Nossaman BD; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H792-802. PubMed ID: 21217076
[TBL] [Abstract][Full Text] [Related]
8. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients.
Lepore JJ; Dec GW; Zapol WM; Bloch KD; Semigran MJ
J Heart Lung Transplant; 2005 Nov; 24(11):1950-6. PubMed ID: 16297803
[TBL] [Abstract][Full Text] [Related]
9. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
Kieler-Jensen N; Lundin S; Ricksten SE
J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
[TBL] [Abstract][Full Text] [Related]
10. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension.
Patterson KW; Deb B; Kavanagh BP; Pearl RG
Pharmacology; 1999 May; 58(5):246-51. PubMed ID: 10087465
[TBL] [Abstract][Full Text] [Related]
11. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets.
Foubert L; De Wolf D; Mareels K; Van Belleghem Y; Reyntjens K; Mortier E; Van Nooten G
Pediatr Res; 2002 Nov; 52(5):730-6. PubMed ID: 12409521
[TBL] [Abstract][Full Text] [Related]
12. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
[TBL] [Abstract][Full Text] [Related]
13. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs.
Ichinose F; Adrie C; Hurford WE; Zapol WM
J Appl Physiol (1985); 1995 Apr; 78(4):1288-95. PubMed ID: 7615435
[TBL] [Abstract][Full Text] [Related]
14. Relaxant effects of carbon monoxide compared with nitric oxide in pulmonary and systemic vessels of newborn piglets.
Villamor E; Pérez-Vizcaíno F; Cogolludo AL; Conde-Oviedo J; Zaragozá-Arnáez F; López-López JG; Tamargo J
Pediatr Res; 2000 Oct; 48(4):546-53. PubMed ID: 11004249
[TBL] [Abstract][Full Text] [Related]
15. Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs.
Freitas CF; Morganti RP; Annichino-Bizzacchi JM; De Nucci G; Antunes E
Clin Exp Pharmacol Physiol; 2007; 34(1-2):10-4. PubMed ID: 17201729
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.
Priviero FB; Baracat JS; Teixeira CE; Claudino MA; De Nucci G; Antunes E
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):728-34. PubMed ID: 16173929
[TBL] [Abstract][Full Text] [Related]
17. Vasoconstriction increases pulmonary nitric oxide synthesis and circulating cyclic GMP.
Wilson PS; Thompson WJ; Moore TM; Khimenko PL; Taylor AE
J Surg Res; 1997 Jun; 70(1):75-83. PubMed ID: 9228932
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
19. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance.
Kieler-Jensen N; Ricksten SE; Stenqvist O; Bergh CH; Lindelöv B; Wennmalm A; Waagstein F; Lundin S
J Heart Lung Transplant; 1994; 13(3):366-75. PubMed ID: 8061011
[TBL] [Abstract][Full Text] [Related]
20. Low doses of inhaled nitric oxide in heart transplant recipients.
Auler Júnior JO; Carmona MJ; Bocchi EA; Bacal F; Fiorelli AI; Stolf NA; Jatene AD
J Heart Lung Transplant; 1996 May; 15(5):443-50. PubMed ID: 8771498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
